Emergent BioSolutions Inc (NYSE:EBS) Share Price

Company Profile

Business description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Contact
300 Professional Drive
GaithersburgMD20879
USA
T: +1 240 631-3200
E: [email protected]
https://www.emergentbiosolutions.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
900

Recommended

Aussie stock exchange remains materially undervalued despite growing cost concerns.

Roy Van Keulen | 29 May 2026

Questions surround Australia’s largest data center developer and its growing pipeline.

Yingqi Tan, CFA | 29 May 2026

The e-commerce business continues its sales momentum despite challenging backdrop.

Johannes Faul, CFA | 28 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,965.00	77.80	0.88%
CAC 40	8,183.34	5.53	-0.07%
DAX 40	25,104.70	12.45	0.05%
Dow JONES (US)	51,032.46	363.49	0.72%
FTSE 100	10,409.28	16.68	-0.16%
HKSE	25,182.39	176.23	0.70%
NASDAQ	26,972.62	55.15	0.20%
Nikkei 225	66,329.50	1,636.38	2.53%
NZX 50 Index	13,244.55	38.44	0.29%
S&P 500	7,580.06	16.43	0.22%
S&P/ASX 200	8,731.70	73.10	0.84%
SSE Composite Index	4,068.57	30.07	-0.73%